Patent ID: 7863246

Claim:
A method for treating amyotrophic lateral sclerosis (ALS) or enhancing the survival of a motor neuron in a subject diagnosed with a motoneuron disease, the method comprising: administering a vascular endothelial growth factor-A (â€œVEGF-Aâ€) protein into the cerebrospinal fluid of the subject for up to at least 4 weeks at a dose within a range between 0.01 Î¼g/kg/day and 0.6 Î¼g/kg/day of the subject's body mass, wherein the VEGF-A protein is selected from the group consisting of: VEGF121, VEGF145; VEGF165 and VEGF189, thus treating the ALS disease or enhancing the survival of a motor neuron in the subject diagnosed with a motoneutron disease.